ClinicalTrials.gg
CompletedNCT06024135FIH CaenUpdated Oct 30, 2026

Safety and Efficacy Assessments of NeoKidney® in ESRD Patients Treated With Short Daily Hemodialysis

An interventional study of NeoKidney in End Stage Renal Disease and ESRD, sponsored by Nextkidney S.A.. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Nextkidney S.A. · Not applicable, Interventional, and Treatment

How we know

Updated Oct 30, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 145 studies in Kidney Failure, Chronic with a site in France — 28 open to participants now, 33 under way, 6 of them phase 3. Kidney Failure, Chronic · France.

Enrollment
101st of 105
5 · median 70
Started
2024
with 9 others
No phase
55 of 145
10 open now
Registered
130th of 145
by date

Among the 145 studies in Kidney Failure, Chronic with a site in France, this one is the 101st largest by enrollment of the 105 interventional ones that give a count, is one of 10 that started in 2024, is one of 55 with no phase, and was the 130th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

28 of the 145 studies in Kidney Failure, Chronic with a site in France are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies in Kidney Failure, Chronic with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical investigation is to asses the safety and efficacy a new sorbent-based hemodialysis device, NeoKidney® in ESRD patients treated with short daily hemodialysis.

Participants (stable SDHD patients) will undergo hemodialysis treatement on the NeoKidney® device at the hospital on a progressive exposition to the device:

  • The first week, patient will be treated once with NeoKidney® on Wednesday
  • The 2nd week the patient will be treated two consecutive days with NeoKidney® (in the middle of the week)
  • On the 3rd week, after approval by the DSMB, the patients will be treated 6 consecutive days, in hospital, with the NeoKidney

All the other sessions will be performed with the patient's usual SDHD device at home except for two sessions prior to NeoKidney® sessions at Week 1 and 2.

03

Conditions studied

  • End Stage Renal Disease
  • ESRD

Keywords

  • Dialysis
  • Hemodialysis
  • Sorbent
  • Short daily hemodialysis
  • SDHD
  • HD
  • ESRD
  • End stage renal disease
  • Dialysate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 18 years or over;
  2. Treated with short-daily hemodialysis (1.5-3 h sessions) 5-6 times a week for at least 3 months;
  3. Estimated Urea removal concentration between [220 to 550] mmol. (Estimation based on the formula: ([Dry Weigh in kg]*] x 0,6)*([) x ([Last pre-dialysis urea concentration in mmol/L]*] x 0,5).
  4. Well-functioning vascular access (native fistula or graft or permanent veinous catheter) defined as:

    • Capable of providing a blood flow rate of ≥200 mL/min, AND
    • Absence of vascular access revision for at least 3 months
  5. For females of reproducible age, negative urinary pregnancy test and use of appropriate method(s);
  6. Ability to understand the and give informed consent;
  7. Willingness and ability to comply with study procedures and to attend all study follow up visits

Exclusion criteria

Exclusion Criteria:

  1. Post-dialysis body weight below 41.0 kg
  2. \<10.0 g/L, or pre-dialysis [Na] \< 132 and > 145 mmol/L, pre-dialysis [K] \< 3.5 and > 6 mmol/L and pre-dialysis [HCO3] \< 15 and > 30 mmol/L in the latest determination, within the 6 weeks prior to enrollment.
  3. One or more pre-dialysis urea concentration \<10 mmol/L or >30mmol/L within the 6 weeks prior to enrollment.
  4. Subjects requiring UF volume >2.0L per 2hr treatment in any dialysis session within 6 weeks prior to enrollment.
  5. Any documented episode of hemolysis within the 6 months prior to enrolment.
  6. Any infection related to the vascular access within the 4 weeks prior to enrolment.
  7. History of impaired liver function (normal Factor V).
  8. Severe uncontrolled arterial hypertension (systolic BP>180mmHg or diastolic BP >104 mmHg).
  9. Known .
  10. Anticipation of a living donor kidney transplantation within the 2 months of the study period.
  11. Pregnant, breast feeding, or planning a pregnancy during the study period.

13. Any known psychosocial problems which may negatively influence dialysis treatment.

14. History of drug and/or alcohol abuse within the last 3 months prior to enrolment.

15. Patients with any serious medical condition which in the opinion of the investigator, may adversely affect the safety of the participant and/or effectiveness of the study

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    NeoKidney therapy

    Every patient will receive NeoKidney therapy which will be referenced to SDHD sessions with the usual device as their own baseline. The study is designed in a way that allows an incremental increase of the ratio of NeoKidney versus SDHD sessions with the usual device. In order to minimize the study burden to the patient, most SDHD sessions with the usual device will be done in the patient's home. The NeoKidney therapy sessions, and 2 SDHD sessions with the usual device will be performed in the study center, thus ensuring the necessary patient care and observation as well as sample collection.

    Device: NeoKidney

Interventions

  • DeviceNeoKidney

    Progressive exposition to NeoKidney device starting with only one NeoKidney therapy on a mid-week day and 5 SDHD sessions with the usual device in week one, followed by 2 NeoKidney therapies and 4 SDHD sessions with the usual device in week 2, and only progressing to a full week on NeoKidney after a safety review.

06

What researchers measure

Primary outcomes

  1. Absence of serious adverse events (SAE) and of serious adverse device effects (SADE).

    To assess the safety of the NeoKidney in a small number (n=3) of patients and HD sessions (9 sessions per patient).

    Time frame: Through the end of last patient follow-up visit, an average of 2 months

  2. Absence of critical change in patient's blood pressure (mm Hg) during treatment

    To assess the safety of the NeoKidney on patient's clinical condition and vital parameters, in a small number (n=3) of patients and HD sessions (9 sessions per patient).

    Time frame: Through the end of last patient follow-up visit, an average of 2 months

  3. Absence of critical change in patient's heart rate (bpm) during treatment

    To assess the safety of the NeoKidney on patient's clinical condition and vital parameters, in a small number (n=3) of patients and HD sessions (9 sessions per patient).

    Time frame: Through the end of last patient follow-up visit, an average of 2 months

  4. Absence of critical change in patient's body temperature (°C) during treatment

    To assess the safety of the NeoKidney on patient's clinical condition and vital parameters, in a small number (n=3) of patients and HD sessions (9 sessions per patient).

    Time frame: Through the end of last patient follow-up visit, an average of 2 months

  5. Absence of critical change in patient's pulse oximetry (% SpO2) during treatment

    To assess the safety of the NeoKidney on patient's clinical condition and vital parameters, in a small number (n=3) of patients and HD sessions (9 sessions per patient).

    Time frame: Through the end of last patient follow-up visit, an average of 2 months

  6. Absence of critical change in bicarbonates (mmol/L) pre- vs post-treatment

    To assess the safety of the NeoKidney on hematology and clinical chemistry pre- vs post-treatment in a small number (n=3) of patients and HD sessions (9 sessions per patient).

    Time frame: Through the end of last patient follow-up visit, an average of 2 months

  7. Absence of critical change in pH pre- vs post-treatment

    To assess the safety of the NeoKidney on hematology and clinical chemistry pre- vs post-treatment in a small number (n=3) of patients and HD sessions (9 sessions per patient).

    Time frame: Through the end of last patient follow-up visit, an average of 2 months

  8. Absence of critical change in LDH (UI/L) pre- vs post-treatment

    To assess the safety of the NeoKidney on hematology and clinical chemistry pre- vs post-treatment in a small number (n=3) of patients and HD sessions (9 sessions per patient).

    Time frame: Through the end of last patient follow-up visit, an average of 2 months

  9. Absence of critical change in Haptoglobin (g/L) pre- vs post-treatment

    To assess the safety of the NeoKidney on hematology and clinical chemistry pre- vs post-treatment in a small number (n=3) of patients and HD sessions (9 sessions per patient).

    Time frame: Through the end of last patient follow-up visit, an average of 2 months

  10. Absence of critical change in Sodium (mmol/L) pre- vs post-treatment

    To assess the safety of the NeoKidney on hematology and clinical chemistry pre- vs post-treatment in a small number (n=3) of patients and HD sessions (9 sessions per patient).

    Time frame: Through the end of last patient follow-up visit, an average of 2 months

  11. Absence of critical change in Potassium (mmol/L) pre- vs post-treatment

    To assess the safety of the NeoKidney on hematology and clinical chemistry pre- vs post-treatment in a small number (n=3) of patients and HD sessions (9 sessions per patient).

    Time frame: Through the end of last patient follow-up visit, an average of 2 months

  12. Absence of critical change in Phosphate (mmol/L) pre- vs post-treatment

    To assess the safety of the NeoKidney on hematology and clinical chemistry pre- vs post-treatment in a small number (n=3) of patients and HD sessions (9 sessions per patient).

    Time frame: Through the end of last patient follow-up visit, an average of 2 months

  13. Absence of critical change in Calcium (mmol/L) pre- vs post-treatment

    To assess the safety of the NeoKidney on hematology and clinical chemistry pre- vs post-treatment in a small number (n=3) of patients and HD sessions (9 sessions per patient).

    Time frame: Through the end of last patient follow-up visit, an average of 2 months

  14. Absence of critical change in Chlorine (mmol/L) pre- vs post-treatment

    To assess the safety of the NeoKidney on hematology and clinical chemistry pre- vs post-treatment in a small number (n=3) of patients and HD sessions (9 sessions per patient).

    Time frame: Through the end of last patient follow-up visit, an average of 2 months

  15. Absence of critical change in Magnesium (mmol/L) pre- vs post-treatment

    To assess the safety of the NeoKidney on hematology and clinical chemistry pre- vs post-treatment in a small number (n=3) of patients and HD sessions (9 sessions per patient).

    Time frame: Through the end of last patient follow-up visit, an average of 2 months

  16. Absence of critical change in Magnesium (µmol/L) pre- vs post-treatment

    To assess the safety of the NeoKidney on hematology and clinical chemistry pre- vs post-treatment in a small number (n=3) of patients and HD sessions (9 sessions per patient).

    Time frame: Through the end of last patient follow-up visit, an average of 2 months

07

Study locations

1 site
  • CHU de Caen
    Caen, Normandy 14000, France
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Jul 2024, 4 months.

Of 78 industry-sponsored interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 4 months is below that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Jun 2024 → Jul 2024 and completion Jun 2024 → Jul 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2023
First posted
Sep 6, 2023
StartActual
Mar 11, 2024
Primary completionActual
Jul 23, 2024was Jun 2024
CompletionActual
Jul 23, 2024was Jun 2024
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 30, 2026
Sites
1 site added, 1 site removed
Show site
  • CHU de Caen · Caen, France
Show 1 removed
  • CHU de Caen · Caen, France
Oct 30, 2026
Primary completion
Jun 2024→Jul 23, 2024 (actual)
Oct 30, 2026
Study completion
Jun 2024→Jul 23, 2024 (actual)
Oct 30, 2026
Enrollment
3 (estimated)→5 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • CHU de Caen · Caen, France
    Show 1 removed
    • CHU de Caen · Caen, France
    Primary completion Jun 2024→Jul 23, 2024 (now actual)
    Study completion Jun 2024→Jul 23, 2024 (now actual)
    Enrollment 3 (estimated)→5 (actual)
    + 4 other changes: verification date, criteria formatting, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06024135
Lead sponsor
Nextkidney S.A.
Collaborators
Monitoring Force Group
Responsible party
Sponsor
First posted
Sep 6, 2023
Start date
Mar 11, 2024
Primary completion
Jul 23, 2024
Completion
Jul 23, 2024
Last update
Oct 30, 2026

Study contacts

Maxence Ficheux, Dr
principal investigator · University Hospital, Caen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion